Dr Jeffrey Goh

MBBS (Monash), FRACP
Medical Oncologist
Become a Patient

Dr Jeffrey Goh is an experienced, compassionate medical oncologist with a strong commitment to achieving the best possible outcome for his patients. He combines an active interest in research and clinical trials with an empathetic approach to care, to support the physical and emotional needs of his patients throughout their cancer journey.

Biography

Dr Jeffrey Goh is an experienced medical oncologist consulting at Icon Cancer Centre Chermside and Icon Cancer Centre Greenslopes. In 1996, he completed his Bachelor of Medicine, Bachelor of Surgery at Monash University and moved from Adelaide to Brisbane to establish his medical career at Greenslopes Private Hospital as a haematology and oncology registrar in 2002. Dr Goh subsequently held a position as a laboratory and clinical haematology registrar at the Princess Alexandra Hospital in 2003. He completed his three years of advanced specialist medical oncology training in Brisbane and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 2007.

Dr Goh represented the Queensland Medical Oncology Advanced Trainees within the Medical Oncology Group of Australia (MOGA) in 2007 prior to his appointment as staff medical oncologist at Royal Brisbane & Women’s Hospital (RBWH) in December 2008. Dr Goh commenced sessional private medical oncology practice as a Visiting Medical Officer (VMO) at Greenslopes Private Hospital (GPH) in 2008 and at Icon Cancer Centre Chermside in early 2010.

Dr Goh is actively involved in numerous clinical trials and acted as principal investigator (PI) in a number of phase I/Ib, II and III gynaecological oncology, urological malignancy and early phase drug trials at RBWH, Icon and GPH. He is also a co-investigator in numerous other multi-centre clinical trials in oncology.

Dr Goh maintains an active interest in clinical research and is a member of several leading cancer trial groups including the Australian and New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP), American Society of Clinical Oncology (ASCO), Australasian Lung Cancer Trialist Group (ALTG) and European Society of Medical Oncology (ESMO). He was previously a Board Member and chair of the QA Committee of the Australia & New Zealand Gynaecological Oncology Group (ANZGOG) and is the current Chair of the Cervical Cancer Tumour Type Working Group of ANZGOG.

Dr Goh maintains a significant part-time role as Senior Staff Specialist at RBWH and is a senior lecturer; he is co-supervisor of PhD candidates at the University of Queensland. He is also involved with mentoring advanced trainee registrars in Medical Oncology at RBWH. Additionally, Dr Goh is a member of both the Research Committee and Medical Advisory Committee (MAC) at Icon. His clinical experience covers a broad range of solid tumour malignancies, with special clinical interest in gynaecological, genitourinary and colorectal cancers, in addition to phase I/Ib clinical trials.

Affiliations & Memberships

  • Australasian Lung Cancer Trialist Group (ALTG)
  • Australian & New Zealand Gynaecological Oncology Group (ANZGOG)
  • Australian and New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP)
  • American Society of Clinical Oncology (ASCO)
  • Cooperative Trials Group for Neuro-Oncology (COGNO)
  • European Society of Medical Oncology (ESMO)
  • Royal Australasian College of Physicians (RACP)

Special Interests

Dr Jeffrey Goh accepts referrals for all cancer types, with a special clinical interest in:
  • Clinical trials
  • Colorectal cancer
  • Genitourinary cancer
  • Gynaecological cancer

Icon Locations

Chermside View centre
Greenslopes View centre

Visiting Locations

  • Royal Brisbane and Women’s Hospital

Publications

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O’Malley, Deborah K Armstrong, Jesus Garcia-Donas, Elizabeth M Swisher, Anne Floquet, Gottfried E Konecny, Iain A McNeish, Clare L Scott, Terri Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline Grace, Thomas C Harding, Mitch Raponi, James Sun, Kevin K Lin, Heidi Giordano, Jonathan A Ledermann. The Lancet, 2017; 390(10106):1949-1961. 

     

  • Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial (CAN-003). J. Gray, B. Benigno, J. Berek, J. Chang, J. Mason, L. Mileshkin, P. Mitchell, M. Moradi, F. O. Recio, C. M. Michener, A. Alvarez Secord, N E. Tchabo, J. K. Chan, J. Young, H. Kohrt, S. E. Gargosky and J.C. Goh. Journal for ImmunoTherapy of Cancer, 2016; 4:34.

  • Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio,Satoshi Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend, Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein, Johann Sebastian de Bono. Journal of Clinical Oncology, 2019. 

  • Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer. Sarah P BlagdenAnne L HamiltonLinda MileshkinShirley WongAgnieszka MichaelMarcia HallJeffrey C Goh, Alla S LisyanskayaMichelle DeSilvioEleni FrangouEuan A StronachPrashanth GopalakrishnaTarek M Meniawy, Hani Gabra. Clinical Cancer Research, 2018; 25(5): 2277.

  • Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Michael Friedlander, Susana Banerjee, Linda Mileshkin, Clare Scott, Catherine Shannon, Jeffrey Goh. Asia-Pacific Journal of Clinical Oncology, 2016; 12(4): 323-331.

View all Doctors

Search